{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:48:18Z","timestamp":1780105698617,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.clinthera.2009.02.004","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T11:45:18Z","timestamp":1237463118000},"page":"328-335","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Andrew R.","family":"Blight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Herbert R.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.02.004_bib1","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1152\/jn.1996.75.6.2629","article-title":"Characterization of six voltage-gated K+ currents in adult rat sensory neurons","volume":"75","author":"Gold","year":"1996","journal-title":"J Neurophysiol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1749-6632.1999.tb11293.x","article-title":"Molecular diversity of K+ channels","volume":"868","author":"Coetzee","year":"1999","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.clinthera.2009.02.004_bib3","first-page":"317","article-title":"Pharmacological actions of aminopyridines and related compounds","volume":"2","author":"Bowman","year":"1981","journal-title":"Rev Pure Appl Pharmacol Sci."},{"key":"10.1016\/j.clinthera.2009.02.004_bib4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres","volume":"283","author":"Sherratt","year":"1980","journal-title":"Nature."},{"key":"10.1016\/j.clinthera.2009.02.004_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0006-8993(85)91049-2","article-title":"4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve","volume":"328","author":"Targ","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.clinthera.2009.02.004_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0361-9230(89)90126-3","article-title":"Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury","volume":"22","author":"Blight","year":"1989","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.clinthera.2009.02.004_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0306-4522(96)00477-0","article-title":"Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord","volume":"77","author":"Shi","year":"1997","journal-title":"Neuroscience."},{"key":"10.1016\/j.clinthera.2009.02.004_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-8993(78)90409-2","article-title":"Effects of 4-aminopyridine on neuromuscular transmission","volume":"153","author":"Lundh","year":"1978","journal-title":"Brain Res."},{"key":"10.1016\/j.clinthera.2009.02.004_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mus.880030202","article-title":"Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission","volume":"3","author":"Kim","year":"1980","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.clinthera.2009.02.004_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/brain\/123.1.171","article-title":"Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension","volume":"123","author":"Smith","year":"2000","journal-title":"Brain."},{"key":"10.1016\/j.clinthera.2009.02.004_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.42.2.171","article-title":"Effects of 4-aminopyridine in myasthenia gravis","volume":"42","author":"Lundh","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2009.02.004_bib12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.40.11.1109","article-title":"4-Aminopyridine\u2014a new drug tested in the treatment of Eaton-Lambert syndrome","volume":"40","author":"Lundh","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2009.02.004_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/bja\/50.4.383","article-title":"Effects of 4-aminopyridine in Eaton Lambert Syndrome","volume":"50","author":"Agoston","year":"1978","journal-title":"Br J Anaesth."},{"key":"10.1016\/j.clinthera.2009.02.004_bib14","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","article-title":"Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine","volume":"62","author":"Strupp","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.02.004_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/jnnp.2004.045716","article-title":"4-Aminopyridine restores visual ocular motor function in upbeat nystagmus","volume":"76","author":"Glasauer","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2009.02.004_bib16","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/brain\/awm172","article-title":"4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus","volume":"130","author":"Kalla","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.clinthera.2009.02.004_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/neu.1993.10.1","article-title":"4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients","volume":"10","author":"Hansebout","year":"1993","journal-title":"J Neurotrauma."},{"key":"10.1016\/j.clinthera.2009.02.004_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.sc.3100559","article-title":"Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases","volume":"36","author":"Potter","year":"1998","journal-title":"Spinal Cord."},{"key":"10.1016\/j.clinthera.2009.02.004_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1592\/phco.19.9.713.31540","article-title":"Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial","volume":"19","author":"Segal","year":"1999","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2009.02.004_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s004150170111","article-title":"Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury","volume":"248","author":"van der Bruggen","year":"2001","journal-title":"J Neurol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.sc.3101947","article-title":"Phase 2 trial of sustained-release fampridine in chronic spinal cord injury","volume":"45","author":"Cardenas","year":"2007","journal-title":"Spinal Cord."},{"key":"10.1016\/j.clinthera.2009.02.004_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ana.410210113","article-title":"4-Aminopyridine improves clinical signs in multiple sclerosis","volume":"21","author":"Stefoski","year":"1987","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.410270215","article-title":"Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis","volume":"27","author":"Davis","year":"1990","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":"The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.02.004_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/archneur.1994.00540150090022","article-title":"4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety","volume":"51","author":"Polman","year":"1994","journal-title":"Arch Neurol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":"Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.02.004_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","article-title":"Fampridine-SR in multiple sclerosis: A randomized, doubleblind, placebo-controlled, doseranging study","volume":"13","author":"Goodman","year":"2007","journal-title":"Mult Scler."},{"key":"10.1016\/j.clinthera.2009.02.004_bib28","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.02.004_bib29","series-title":"Lancet","article-title":"Sustained release of oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial","author":"Goodman","year":"2009"},{"key":"10.1016\/j.clinthera.2009.02.004_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/bja\/53.6.567","article-title":"Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation","volume":"53","author":"Evenhuis","year":"1981","journal-title":"Br J Anaesth."},{"key":"10.1016\/j.clinthera.2009.02.004_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/clpt.1982.82","article-title":"4-Aminopyridine kinetics","volume":"31","author":"Uges","year":"1982","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.02.004_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-199306000-00002","article-title":"4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety","volume":"16","author":"Van Diemen","year":"1993","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270003251388","article-title":"Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury","volume":"43","author":"Hayes","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.02.004_bib34","series-title":"Handbook of Basic Pharmacokinetics\u2014Including Clinical Applications","author":"Ritschel","year":"1992"},{"key":"10.1016\/j.clinthera.2009.02.004_bib35","series-title":"Primer of Biostatistics","author":"Glantz","year":"1981"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T23:30:29Z","timestamp":1558222229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0149291809000472"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}